Unlock instant, AI-driven research and patent intelligence for your innovation.

Therapeutic Agent for Neuroblastoma Targeting ARID3b

a neuroblastoma and therapy agent technology, applied in the field of compositions for treating neuroblastoma, can solve the problems of preventing the development of a new treatment method, affecting the treatment effect of patients of one year or older, and affecting the treatment effect of patients

Inactive Publication Date: 2010-06-03
RIKEN
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

"The present invention is about a composition for treating neuroblastoma that contains an ARID3b inhibitor. The inventors found that the ARID3b molecule is important for the growth and maintenance of neuroblastoma cells and is involved in canceration of cells. They also found that the ARID3b molecule is expressed in cranial mesenchymal cells and is important for their survival. The invention provides a method of screening for an ARID3b inhibitor, a method of inhibiting ARID3b, and a kit for diagnosing neuroblastoma. The technical effect of the invention is to provide a new treatment for neuroblastoma that targets the molecule ARID3b."

Problems solved by technology

In particular, the current therapy is not effective for many of cases of patients of one year old or older having highly advanced tumors, or cases with the above-mentioned amplification of MYCN oncogene or deletion of chromosome 1p.
Although there is an urgent need for establishment of a method of treating neuroblastoma, the above has been a principal cause that impedes development of a new treatment method (Non-patent Document 1).

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Therapeutic Agent for Neuroblastoma Targeting ARID3b
  • Therapeutic Agent for Neuroblastoma Targeting ARID3b
  • Therapeutic Agent for Neuroblastoma Targeting ARID3b

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0047]Expression of ARID3b mRNA was examined for five neuroblastoma cell lines. SH-SY5Y (ATCC CRL-2266), TGW (Iwasaki, I. et al., Cancer Chemother. Pharmacol., 49:438-444 (2002)), CHP-126 (Schlesinger, H. R. et al., Cancer Res., 36:3094-3100 (1976)), NBLS and IMR (ATCC CCL-127) were used as neuroblastoma cell lines. Furthermore, K562 (chronic myelogenous leukemia, ATCC CCL-243) was used as a control. A medium consisting of 45% Dulbecco's minimum essential medium (D-MEM, Invitrogen), 45% Ham's F-12 medium (Invitrogen) and 10% fetal bovine serum (FBS, JRL) was used for the cultivation of neuroblastoma cell lines. A medium consisting of 90% D-MEM and 10% FBS was used for other cell lines. RNA was extracted from each cell line according to a conventional method, and subjected to Northern blot hybridization using human ARID3b DNA (SEQ ID NO:8) as a probe. Detection of actin mRNA was carried out in a similar manner. The results are shown in FIG. 1A. As shown in FIG. 1A, although the expre...

example 2

[0050]Influence of forced expression of ARID3b on in vitro malignancy of a cell was examined using growth ability and colony formation ability as indexes. A retrovirus having human ARID3b DNA (SEQ ID NO:8) being inserted was constructed. The retrovirus contained in MSCV Retrovirus Expression System (Cat. No. 634401) which is commercially available from Clontech was used as a retrovirus after substituting IRES GFP for the drug resistance gene portion. This recombinant retrovirus was used to infect the neuroblastoma cell line SH-SY5Y to forcibly express ARID3b and the cell number was measured over time. For SH-SY5Y, expression of ARID3b was observed in Example 1, and it was known that amplification of MYCN oncogene is not found. The results are shown in FIG. 2A. In the figure, diamonds (♦) represent results of infection with the retrovirus having ARID3b DNA being inserted, and squares (▪) represent results of infection with the vector without the insert DNA. As shown in FIG. 2A, the c...

example 3

[0054]Influence of forced expression of ARID3b on canceration of a primary cultured cell was examined using senescence and immortalization during passage cultures as indexes. The retrovirus having human ARID3b DNA being inserted used in Example 2 was used to infect mouse primary cultured fibroblasts isolated from a fetus. A medium consisting of 90% D-MEM and 10% FBS was used for the cultivation of primary cultured fibroblasts. The cells were passaged at intervals of two or three days by washing with Dulbecco's phosphate-buffered saline (PBS, Invitrogen), detaching from dishes using 0.05% (w / v) trypsin-EDTA (Invitrogen), and diluting 5-fold. The cells were counted upon passages. The results are shown in FIG. 4. In the figure, diamonds (♦) represent results of infection with the retrovirus having ARID3b DNA being inserted and squares (▪) represent results of infection with the vector without the insert DNA. As shown in FIG. 4, when the primary cultured fibroblasts infected with the ve...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
timeaaaaaaaaaa
frequencyaaaaaaaaaa
compositionaaaaaaaaaa
Login to View More

Abstract

It is intended to provide a therapeutic agent for neuroblastoma. More particularly, it is intended to provide the therapeutic agent for neuroblastoma containing an ARID3b inhibitor.

Description

TECHNICAL FIELD[0001]The present invention relates to a composition for treating neuroblastoma which contains an ARID3b inhibitor.BACKGROUND ART[0002]Neuroblastoma is a disease that frequently occurs principally in children of five years old or younger, and of which the frequency is the highest among solid tumors in infants. As to genetic features associated with neuroblastoma, amplification of MYCN oncogene, deletion of chromosome 1p and the like are known. In particular, the current therapy is not effective for many of cases of patients of one year old or older having highly advanced tumors, or cases with the above-mentioned amplification of MYCN oncogene or deletion of chromosome 1p. Although the relationship between the amplification of MYCN oncogene (found in about 20% of the disease cases) and neuroblastoma was suggested in the mid-1980s, there has been no report on a molecule that surely has an important function specific for neuroblastoma since then, and almost nothing has b...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C12Q1/68C12Q1/02C12N5/06G01N33/68C07H21/02A01K67/00C07K16/18G01N33/536C12N15/113
CPCA61K48/00C07K14/47C12N15/113C12N2310/11G01N2500/04C12Q1/6886C12Q2600/118G01N33/57407C12N2310/14A61P35/00A61P43/00
Inventor ERA, TAKUMINISHIKAWA, SHIN-ICHI
Owner RIKEN